Lymecycline

Lymecycline

Clinical data
Pregnancy category	? (Aust)
Routes of administration	oral
ATC code	J01AA04 (WHO)
Legal status
Legal status	Schedule 4 (Aust)
Pharmacokinetic data
Bioavailability	100% (oral)
Metabolism	?
Elimination half-life	?
Excretion	renal
Identifiers
IUPAC name 2-(amino-hydroxy-methylidene)- 7-chloro-4-dimethylamino- 6,10,11,12a- tetrahydroxy-6- methyl- 4,4a,5,5a-tetrahydrotetracene-1 ,3,12-trione
CAS Number	992-21-2
PubChem CID	23649
DrugBank	APRD00565
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	CH23N2O8
Molar mass	478.879

WikiDoc Resources for Lymecycline
Articles
Most recent articles on Lymecycline Most cited articles on Lymecycline Review articles on Lymecycline Articles on Lymecycline in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Lymecycline Images of Lymecycline Photos of Lymecycline Podcasts & MP3s on Lymecycline Videos on Lymecycline
Evidence Based Medicine
Cochrane Collaboration on Lymecycline Bandolier on Lymecycline TRIP on Lymecycline
Clinical Trials
Ongoing Trials on Lymecycline at Clinical Trials.gov Trial results on Lymecycline Clinical Trials on Lymecycline at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Lymecycline NICE Guidance on Lymecycline NHS PRODIGY Guidance FDA on Lymecycline CDC on Lymecycline
Books
Books on Lymecycline
News
Lymecycline in the news Be alerted to news on Lymecycline News trends on Lymecycline
Commentary
Blogs on Lymecycline
Definitions
Definitions of Lymecycline
Patient Resources / Community
Patient resources on Lymecycline Discussion groups on Lymecycline Patient Handouts on Lymecycline Directions to Hospitals Treating Lymecycline Risk calculators and risk factors for Lymecycline
Healthcare Provider Resources
Symptoms of Lymecycline Causes & Risk Factors for Lymecycline Diagnostic studies for Lymecycline Treatment of Lymecycline
Continuing Medical Education (CME)
CME Programs on Lymecycline
International
Lymecycline en Espanol Lymecycline en Francais
Business
Lymecycline in the Marketplace Patents on Lymecycline
Experimental / Informatics
List of terms related to Lymecycline

Lymecycline is a tetracycline broad-spectrum antibiotic marketed by the pharmeceutical company Galderma[1]. It is approximately 5000 times more soluble than tetracycline base and is unique amongst tetracyclines in that it is absorbed by the "active transport" process across the intestinal wall, making use of the same fast and efficient mechanism by which carbohydrates are absorbed.

The greater absorption of Lymecycline allows for lower dosages to be used; the standard dose of 408 mg is equivalent to 300 mg tetracycline base, and in its action to 500 mg tetracycline hydrochloride. Lymecycline, unlike tetracycline hydrochloride, is soluble at all physiological pH values.

History

Lymecycline was released onto the pharmaceutical market in 1963.

Indications

Lymecycline, like other Tetracyclines, is used to treat a range of infections (see Tetracycline antibiotics group). Its better absorption profile makes it preferable to tetracycline for moderately severe acne and typically prescribed for 8 weeks at a time, but alternatives should be sought if no improvement occurs by 3 months.

Dosage

The standard dose is 408mg (one capsule) twelve hourly by mouth. In particularly severe infections this dose may be increased to 1.224-1.632mg (three or four capsules) daily.

The 408mg once daily dosage for acne aids good drug compliance.

Lymecycline capsules

Formulation

Capsules containing 408mg of Lymecycline (brand name Tetrlysal 300).

References

1. ^ New Zealand Datasheet August 2003
2. ^ British National Formulary 45 March 2003

See also

Timeline of antibiotics